Intellia (NASDAQ:NTLA) announces a research collaboration with privately held GEMoaB, wherein the companies will combine GEMoaB’s proprietary RevCAR technology platform with Intellia’s proprietary genome editing technologies to discover and develop allogeneic cellular immunotherapies for cancers and inflammatory diseases.
Under the terms of the agreement, GEMoaB will receive payments for each product based on target reservation and selection, achievement of milestones as well as tiered royalties based on net sales.
Intellia will lead the collaboration, and be responsible for clinical development and commercialization.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.